Collegium Showcases Innovative ADHD Treatment at National Conference
Presenting at a Premier Pediatric Nursing Conference
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) has announced it will feature two poster presentations at the National Association of Pediatric Nurse Practitioners (NAPNAP) 46th National Conference on Pediatric Health Care. This key event is set to take place in Chicago, where medical professionals gather to exchange insights on pediatric health care.
Highlighting Real-World Data for Jornay PM
The presentations will focus on Jornay PM, a differentiated neuropsychiatry product from Collegium. This medication is specifically designed to treat attention deficit hyperactivity disorder (ADHD) in patients aged six years and older. With an aim to improve lives impacted by serious medical conditions, Collegium emphasizes the real-world benefits of Jornay PM.
Details of the Presentations
Attendees can look forward to viewing the following poster sessions, which will showcase robust data analyses:
- Poster Title: #9: Real-World Persistence and Adherence with Delayed-Release/Extended-Release Methylphenidate from a Large US Claims Database Analysis
- Authors: Vamshi Ruthwik Anupindi, MS; Swapna Munnangi, PhD; Mitchell DeKoven, MHSA; Michelle D. Po, PhD; Cassandra L. Uchida, PhD; Lewis E. Warrington, MD
- Poster Title: #10: Real-World Utilization of Delayed-Release/Extended-Release Methylphenidate: Demographic and Dosing Data from a Large US Claims Database Analysis
- Authors: Same as above.
Expert Insights on Jornay PM
Dr. Thomas Smith, the Chief Medical Officer of Collegium, expressed enthusiasm for sharing the real-world data at NAPNAP. He highlighted Collegium's commitment to offering innovative therapies that enhance patient care in ADHD management.
Understanding ADHD
ADHD is one of the most prevalent psychiatric conditions among children, characterized by variable behavioral symptoms. Typically, it presents during childhood and can continue into adulthood. Children suffering from ADHD often face challenges with attention, impulse control, and hyperactivity, leading to potential disruptions during morning routines and school activities.
All About Jornay PM
Jornay PM is a CNS stimulant that works by affecting chemicals in the brain that contribute to impulse control and hyperactivity. This medication is particularly designed to cater to the needs of children and adolescents dealing with ADHD, and it is crucial to manage its use due to its classification as a federally controlled substance.
Important Safety Information
While Jornay PM can be highly effective, it is important to note that it may come with risks. Safety precautions include monitoring for signs of abuse, dependency, and potential serious side effects such as cardiovascular issues and psychiatric effects. Patients are advised to keep Jornay PM secure to prevent misuse.
About Collegium Pharmaceutical, Inc.
Collegium is dedicated to becoming a leading biopharmaceutical company focused on improving the lives of individuals with serious medical conditions. With a robust portfolio of medications aimed at responsible pain management and now including Jornay PM, Collegium is poised to expand its presence in the neuropsychiatry realm while strategically growing its commercial initiatives.
Frequently Asked Questions
What is the focus of Collegium's poster presentations?
The presentations will focus on real-world data regarding the effectiveness of Jornay PM and its implications for ADHD treatment.
Who will be presenting at the conference?
The authors include experts in the field, such as Vamshi Ruthwik Anupindi and Swapna Munnangi, among others.
When will the NAPNAP conference take place?
The conference will occur over several days, from March 10 to 13, with specific times for poster viewings.
What is Jornay PM used for?
Jornay PM is used for treating ADHD in individuals aged six and older, helping to improve focus, attention, and reduce impulsivity.
What safety precautions are associated with Jornay PM?
It's critical to monitor for potential side effects and signs of abuse, given that Jornay PM is a controlled substance.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
